Fusion Pharmaceuticals plans to open state-of-the-art radiopharmaceutical manufacturing facility.
This facility covers an area of 27,000 square feet and is designed to follow strict quality standards.
The new facility will create more than 100,000 doses of these targeted alpha therapies every year. This state-of-the-art facility is designed with the capacity to engage in both clinical and commercial scale manufacturing.
Its primary objective is to cater to the production needs of targeted alpha therapies (TATs) in response to the growing demand within the pipeline.
This facility is strategically situated alongside the research and development labs and McMaster University and enables to easily hire experienced talent to execute on clinical and future commercial plans.
The facility' is expected to launch in 2024.
Name Fusion Pharmaceuticals
Type New Construction